259 related articles for article (PubMed ID: 18497829)
1. Anti-VEGF therapy: comparison of current and future agents.
Pieramici DJ; Rabena MD
Eye (Lond); 2008 Oct; 22(10):1330-6. PubMed ID: 18497829
[TBL] [Abstract][Full Text] [Related]
2. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
Tolentino M
Surv Ophthalmol; 2011; 56(2):95-113. PubMed ID: 21335144
[TBL] [Abstract][Full Text] [Related]
3. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs].
Rodrigues EB; Rossi EE; Grumann Junior A; Meyer CH; Ho AC
Arq Bras Oftalmol; 2006; 69(5):756-65. PubMed ID: 17187150
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
van Wijngaarden P; Qureshi SH
Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
[TBL] [Abstract][Full Text] [Related]
7. Antivascular endothelial growth factors in age-related macular degeneration.
Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
[TBL] [Abstract][Full Text] [Related]
8. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
[TBL] [Abstract][Full Text] [Related]
9. Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series.
Kohly RP; Muni RH; Kertes PJ; Lam WC
Can J Ophthalmol; 2011 Feb; 46(1):46-50. PubMed ID: 21283157
[TBL] [Abstract][Full Text] [Related]
10. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Nelson M
Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
[No Abstract] [Full Text] [Related]
11. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
12. [VEGF inhibitors in ophthalmology].
Thys J; Dupont G; Rakic JM
Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468
[TBL] [Abstract][Full Text] [Related]
13. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology of choroidal neovascularization.
Lu M; Adamis AP
Ophthalmol Clin North Am; 2006 Sep; 19(3):323-34. PubMed ID: 16935207
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
16. What we don't know about avastin might hurt us.
Gillies MC
Arch Ophthalmol; 2006 Oct; 124(10):1478-9. PubMed ID: 17030717
[No Abstract] [Full Text] [Related]
17. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
Nagpal M; Nagpal K; Nagpal PN
Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
[TBL] [Abstract][Full Text] [Related]
18. Neovascular age-related macular degeneration.
Veritti D; Sarao V; Lanzetta P
Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
[TBL] [Abstract][Full Text] [Related]
19. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Shah GK; Sang DN; Hughes MS
Retina; 2009 Feb; 29(2):133-48. PubMed ID: 19202423
[TBL] [Abstract][Full Text] [Related]
20. A view on new drugs for macular degeneration.
Drug Ther Bull; 2007 Jul; 45(7):49-52. PubMed ID: 17718304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
